Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 23

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 23
---
, 2025, we reported new preclinical results showing that its lead compound, Telomir-1, restored mitochondrial function without
triggering oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome (HGPS).

●
On August 7, 2025, we reported new preclinical data revealing that Telomir-1 potently inhibits three key histone demethylase enzymes-JMJD3,
FBXL10, and FBXL11-that regulate gene expression through epigenetic mechanisms. These enzymes are known to influence tumor progression,
immune response, metabolic function, and neuroinflammation.

●
On August 27, 2025, we sold a total of 350,000 shares of our common stock, no par value, in block sales to institutional investors, at
an average price of $1.95 per share, (a premium to the prior day’s close), through our at-the-market equity offering facility.

●
On August 28, 2025, we sold a total of 1,200,000 shares of our common stock, no par value, in block sales to institutional investors,
at an average price of $1.82 per share, (a premium to the prior day’s close), through our at-the-market equity offering facility.

●
On August 28, 2025, we announced new in vitro results that expand understanding of our lead drug candidate, Telomir-1. In studies conducted
by Eurofins Discovery, Telomir-1 was shown to potently inhibit UTX (KDM6A), an enzyme that acts like an “eraser” of chemical
tags on DNA packaging proteins. These tags, known as DNA methylation and histone marks, are part of the body’s system for deciding
which genes are turned on or off - much like switches on a circuit board.

●
On September 9, 2025 we reported new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor
suppressor gene silenced in many aggressive cancers.

●
On September 18, 2025, we reported new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of
the KDM5 histone demethylase family. Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors
and activate inflammatory programs. Blocking these enzymes